147 related articles for article (PubMed ID: 36916944)
1. Efavirenz-Based Antiretroviral Therapy but Not Pregnancy Increased Unbound Piperaquine Exposure in Women during Malaria Chemoprevention.
Hong H; Aslam-Mir U; Kajubi R; Wallender E; Mwebaza N; Dorsey G; Rosenthal PJ; Aweeka FT; Huang L
Antimicrob Agents Chemother; 2023 Apr; 67(4):e0142722. PubMed ID: 36916944
[TBL] [Abstract][Full Text] [Related]
2. Piperaquine Exposure Is Altered by Pregnancy, HIV, and Nutritional Status in Ugandan Women.
Hughes E; Imperial M; Wallender E; Kajubi R; Huang L; Jagannathan P; Zhang N; Kakuru A; Natureeba P; Mwima MW; Muhindo M; Mwebaza N; Clark TD; Opira B; Nakalembe M; Havlir D; Kamya M; Rosenthal PJ; Dorsey G; Aweeka F; Savic RM
Antimicrob Agents Chemother; 2020 Nov; 64(12):. PubMed ID: 33020153
[TBL] [Abstract][Full Text] [Related]
3. Antiretroviral Therapy With Efavirenz Accentuates Pregnancy-Associated Reduction of Dihydroartemisinin-Piperaquine Exposure During Malaria Chemoprevention.
Kajubi R; Huang L; Jagannathan P; Chamankhah N; Were M; Ruel T; Koss CA; Kakuru A; Mwebaza N; Kamya M; Havlir D; Dorsey G; Rosenthal PJ; Aweeka FT
Clin Pharmacol Ther; 2017 Sep; 102(3):520-528. PubMed ID: 28187497
[TBL] [Abstract][Full Text] [Related]
4. Impact of Dolutegravir-Based Antiretroviral Therapy on Piperaquine Exposure following Dihydroartemisinin-Piperaquine Intermittent Preventive Treatment of Malaria in Pregnant Women Living with HIV.
Banda CG; Nkosi D; Allen E; Workman L; Madanitsa M; Chirwa M; Kapulula M; Muyaya S; Munharo S; Tarning J; Phiri KS; Mwapasa V; Ter Kuile FO; Maartens G; Barnes KI
Antimicrob Agents Chemother; 2022 Dec; 66(12):e0058422. PubMed ID: 36374096
[TBL] [Abstract][Full Text] [Related]
5. Predicting Optimal Dihydroartemisinin-Piperaquine Regimens to Prevent Malaria During Pregnancy for Human Immunodeficiency Virus-Infected Women Receiving Efavirenz.
Wallender E; Vucicevic K; Jagannathan P; Huang L; Natureeba P; Kakuru A; Muhindo M; Nakalembe M; Havlir D; Kamya M; Aweeka F; Dorsey G; Rosenthal PJ; Savic RM
J Infect Dis; 2018 Mar; 217(6):964-972. PubMed ID: 29272443
[TBL] [Abstract][Full Text] [Related]
6. Variable piperaquine exposure significantly impacts protective efficacy of monthly dihydroartemisinin-piperaquine for the prevention of malaria in Ugandan children.
Sundell K; Jagannathan P; Huang L; Bigira V; Kapisi J; Kakuru MM; Savic R; Kamya MR; Dorsey G; Aweeka F
Malar J; 2015 Sep; 14():368. PubMed ID: 26403465
[TBL] [Abstract][Full Text] [Related]
7. Population pharmacokinetics, tolerability, and safety of dihydroartemisinin-piperaquine and sulfadoxine-pyrimethamine-piperaquine in pregnant and nonpregnant Papua New Guinean women.
Benjamin JM; Moore BR; Salman S; Page-Sharp M; Tawat S; Yadi G; Lorry L; Siba PM; Batty KT; Robinson LJ; Mueller I; Davis TM
Antimicrob Agents Chemother; 2015 Jul; 59(7):4260-71. PubMed ID: 25963981
[TBL] [Abstract][Full Text] [Related]
8. Piperaquine-Induced QTc Prolongation Decreases With Repeated Monthly Dihydroartemisinin-Piperaquine Dosing in Pregnant Ugandan Women.
Hughes E; Wallender E; Kajubi R; Jagannathan P; Ochieng T; Kakuru A; Kamya MR; Clark TD; Rosenthal PJ; Dorsey G; Aweeka F; Savic RM
Clin Infect Dis; 2022 Aug; 75(3):406-415. PubMed ID: 34864925
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of Piperaquine and Safety Profile of Dihydroartemisinin-Piperaquine Coadministered with Antiretroviral Therapy in Malaria-Uninfected HIV-Positive Malawian Adults.
Banda CG; Dzinjalamala F; Mukaka M; Mallewa J; Maiden V; Terlouw DJ; Lalloo DG; Khoo SH; Mwapasa V
Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29784846
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of dihydroartemisinin and piperaquine in pregnant and nonpregnant women with uncomplicated falciparum malaria.
Rijken MJ; McGready R; Phyo AP; Lindegardh N; Tarning J; Laochan N; Than HH; Mu O; Win AK; Singhasivanon P; White N; Nosten F
Antimicrob Agents Chemother; 2011 Dec; 55(12):5500-6. PubMed ID: 21947392
[TBL] [Abstract][Full Text] [Related]
11. Population pharmacokinetics of dihydroartemisinin and piperaquine in pregnant and nonpregnant women with uncomplicated malaria.
Tarning J; Rijken MJ; McGready R; Phyo AP; Hanpithakpong W; Day NP; White NJ; Nosten F; Lindegardh N
Antimicrob Agents Chemother; 2012 Apr; 56(4):1997-2007. PubMed ID: 22252822
[TBL] [Abstract][Full Text] [Related]
12. Modeling Prevention of Malaria and Selection of Drug Resistance with Different Dosing Schedules of Dihydroartemisinin-Piperaquine Preventive Therapy during Pregnancy in Uganda.
Wallender E; Zhang N; Conrad M; Kakuru A; Muhindo M; Tumwebaze P; Kajubi R; Mota D; Legac J; Jagannathan P; Havlir D; Kamya M; Dorsey G; Aweeka F; Rosenthal PJ; Savic RM
Antimicrob Agents Chemother; 2019 Feb; 63(2):. PubMed ID: 30530597
[TBL] [Abstract][Full Text] [Related]
13. The influence of nevirapine and efavirenz-based anti-retroviral therapy on the pharmacokinetics of lumefantrine and anti-malarial dose recommendation in HIV-malaria co-treatment.
Maganda BA; Ngaimisi E; Kamuhabwa AA; Aklillu E; Minzi OM
Malar J; 2015 Apr; 14():179. PubMed ID: 25906774
[TBL] [Abstract][Full Text] [Related]
14. Effect of dihydroartemisinin/piperaquine for malaria intermittent preventive treatment on dolutegravir exposure in pregnant women living with HIV.
Banda CG; Nkosi D; Allen E; Workman L; Madanitsa M; Chirwa M; Kapulula M; Muyaya S; Munharo S; Wiesner L; Phiri KS; Mwapasa V; Ter Kuile FO; Maartens G; Barnes KI
J Antimicrob Chemother; 2022 May; 77(6):1733-1737. PubMed ID: 35288747
[TBL] [Abstract][Full Text] [Related]
15. Safety, tolerability and pharmacokinetic properties of coadministered azithromycin and piperaquine in pregnant Papua New Guinean women.
Moore BR; Benjamin JM; Auyeung SO; Salman S; Yadi G; Griffin S; Page-Sharp M; Batty KT; Siba PM; Mueller I; Rogerson SJ; Davis TM
Br J Clin Pharmacol; 2016 Jul; 82(1):199-212. PubMed ID: 26889763
[TBL] [Abstract][Full Text] [Related]
16. Rethinking Dosing Regimen Selection of Piperaquine for Malaria Chemoprevention: A Simulation Study.
Sambol NC; Tappero JW; Arinaitwe E; Parikh S
PLoS One; 2016; 11(5):e0154623. PubMed ID: 27182702
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic comparison of two piperaquine-containing artemisinin combination therapies in Papua New Guinean children with uncomplicated malaria.
Salman S; Page-Sharp M; Batty KT; Kose K; Griffin S; Siba PM; Ilett KF; Mueller I; Davis TM
Antimicrob Agents Chemother; 2012 Jun; 56(6):3288-97. PubMed ID: 22470119
[TBL] [Abstract][Full Text] [Related]
18. The application of physiologically based pharmacokinetic modelling to assess the impact of antiretroviral-mediated drug-drug interactions on piperaquine antimalarial therapy during pregnancy.
Olafuyi O; Coleman M; Badhan RKS
Biopharm Drug Dispos; 2017 Nov; 38(8):464-478. PubMed ID: 28710808
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic predictors for recurrent malaria after dihydroartemisinin-piperaquine treatment of uncomplicated malaria in Ugandan infants.
Creek DJ; Bigira V; McCormack S; Arinaitwe E; Wanzira H; Kakuru A; Tappero JW; Sandison TG; Lindegardh N; Nosten F; Aweeka FT; Parikh S
J Infect Dis; 2013 Jun; 207(11):1646-54. PubMed ID: 23447696
[TBL] [Abstract][Full Text] [Related]
20. Effect of Pregnancy on the Pharmacokinetic Interaction between Efavirenz and Lumefantrine in HIV-Malaria Coinfection.
Adegbola A; Abutaima R; Olagunju A; Ijarotimi O; Siccardi M; Owen A; Soyinka J; Bolaji O
Antimicrob Agents Chemother; 2018 Oct; 62(10):. PubMed ID: 30082286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
